Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection
- PMID: 20177954
- DOI: 10.1007/s10792-010-9357-0
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection
Abstract
We report a case of Vogt-Koyanagi-Harada (VKH) disease in a 30-year-old patient who was receiving interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. The intraocular inflammation responded to systemic corticosteroid and mycophenolate mofetil treatment. Physicians should be aware of the association between interferon-alpha and ribavirin therapy for hepatitis C virus infection and the development of VKH disease.
Similar articles
-
[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].J Fr Ophtalmol. 2010 Mar;33(3):185-8. doi: 10.1016/j.jfo.2010.01.009. Epub 2010 Feb 20. J Fr Ophtalmol. 2010. PMID: 20172621 French.
-
Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.J Infect. 2006 Feb;52(2):e59-61. doi: 10.1016/j.jinf.2005.05.005. Epub 2005 Jun 13. J Infect. 2006. PMID: 15951019
-
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.Korean J Hepatol. 2011 Mar;17(1):61-5. doi: 10.3350/kjhep.2011.17.1.61. Korean J Hepatol. 2011. PMID: 21494079 Free PMC article.
-
Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.Ocul Immunol Inflamm. 2019;27(2):229-234. doi: 10.1080/09273948.2017.1373827. Epub 2017 Oct 12. Ocul Immunol Inflamm. 2019. PMID: 29023176 Review.
-
Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.J Gastroenterol. 2004 Nov;39(11):1106-9. doi: 10.1007/s00535-004-1452-4. J Gastroenterol. 2004. PMID: 15580406 Review.
Cited by
-
Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease.Sci Rep. 2024 Jun 8;14(1):13211. doi: 10.1038/s41598-024-63957-1. Sci Rep. 2024. PMID: 38851824 Free PMC article.
-
Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature.World J Clin Cases. 2019 May 6;7(9):1043-1052. doi: 10.12998/wjcc.v7.i9.1043. World J Clin Cases. 2019. PMID: 31123677 Free PMC article.
-
Bibliometric analysis of the Vogt‒Koyanagi‒Harada disease literature.Int Ophthalmol. 2023 Nov;43(11):4137-4150. doi: 10.1007/s10792-023-02815-x. Epub 2023 Aug 8. Int Ophthalmol. 2023. PMID: 37552428 Free PMC article.
-
Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.J Ophthalmic Inflamm Infect. 2023 May 19;13(1):27. doi: 10.1186/s12348-023-00333-6. J Ophthalmic Inflamm Infect. 2023. PMID: 37204477 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources